Advances in biomarker sciences and technology最新文献

{"title":"Therapeutic potential of black seed oil in treating rheumatoid arthritis: Insights on biochemical and genetic analyses of inflammatory signaling transducer","authors":"Mohamed G. Elharrif ,&nbsp;Omnia M. Abdelhamid ,&nbsp;Hussein A. Abdel-Maksoud ,&nbsp;Naglaa F. Alhusseini ,&nbsp;Nihal E. Amer","doi":"10.1016/j.abst.2024.09.002","DOIUrl":"10.1016/j.abst.2024.09.002","url":null,"abstract":"<div><div>Nigella sativa (Black seed) has been a longstanding component of traditional medicine. Rheumatoid arthritis, an autoimmune disorder targeting bone, cartilage, and synovial cells, leads to enduring joint damage due to pathological immune responses. This study aims to assess the effectiveness of black seed oil in treating rheumatoid arthritis using a rat model. Fifty male albino rats were randomly assigned to five groups: control, induced arthritis, induced arthritis treated with black seed oil, induced arthritis treated with hydroxychloroquine, and induced arthritis treated with a combination of black seed oil and hydroxychloroquine. Arthritis was induced in the rats using single dose of 0.1 ml of Complete Freunds Adjuvant. Biochemical and genetic analyses of signaling transducers (IFNγ, IL-4, STAT3, and IL-12) were conducted on blood samples and stifle joints. Results indicated that induced arthritis led to elevated serum AST, ALT activities, creatinine, urea, FBS, RF, Anti-CCP, and CRP, along with reduced serum TAC. Additionally, there was an upregulation of IL-12, IFNγ, and STAT3 genes, and a downregulation of IL-4 gene compared to the normal control group. Treatment with black seed oil or hydroxychloroquine individually demonstrated notable improvements in these parameters, although the combined treatment showed less marked improvement. In conclusion, black seed oil demonstrates potential therapeutic benefits in alleviating the negative impacts of rheumatoid arthritis.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 217-225"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142424717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A brief history of urine examination - From ancient uroscopy to 21st century urinomics","authors":"Tatjana Crnogorac-Jurcevic","doi":"10.1016/j.abst.2024.06.001","DOIUrl":"10.1016/j.abst.2024.06.001","url":null,"abstract":"<div><p>The art of uroscopy (Greek <em>ouron</em>-urine and <em>skopeo</em>-examination), the visual inspection of urine, is as old as the history of mankind. It had seen its ups and downs, was praised and derided, but was ultimately perfected to become a complex visual and tasting examination tool. As centuries passed, it was replaced by urinalysis which was first based on iatrochemical principles and then followed by transmutation into modern biochemical analyses. Recent rapid development of sophisticated ‘omics’ technologies opened new avenues for the exploration of this important body fluid. This brief overview will take a journey through this fascinating history and will give a glimpse of what is to come in the future.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 83-90"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000085/pdfft?md5=a44ecb46dac125f0723bb2767ab8b5ad&pid=1-s2.0-S2543106424000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141401525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring fucosylation in lung cancer: Mechanisms, diagnosis, and therapeutic strategies","authors":"Saima Rafique ,&nbsp;Wei Ge ,&nbsp;Ziyuan Gao ,&nbsp;Yan Chen ,&nbsp;Jun Xia ,&nbsp;Junhong Jiang ,&nbsp;Shuang Yang","doi":"10.1016/j.abst.2024.08.005","DOIUrl":"10.1016/j.abst.2024.08.005","url":null,"abstract":"<div><p>Lung cancer remains a global health crisis, responsible for significant morbidity and mortality. Late-stage diagnosis often limits treatment options and patient survival. Therefore, identifying reliable and sensitive biomarkers for early detection is crucial. Glycosylation, the addition of glycans to protein/RNA/lipid, is a vital cellular process. Normal glycosylation regulates healthy cell function, while alterations, particularly in fucosylation and sialylation, contribute to lung cancer development and progression. These aberrant glycosylation patterns are associated with processes such as immune modulation, cell migration, proliferation, and cell-cell recognition. Fucosylation, a specific type of glycosylation, is frequently altered in lung cancer, with high levels detected in tumors. Understanding the mechanisms behind this altered fucosylation holds immense potential. It can pave the way for the development of novel therapeutic and diagnostic tools for lung cancer. By analyzing specific fucosylation patterns in bodily fluids, it could lead to early-stage diagnosis. This review delves into the mechanisms of fucosylation in lung cancer initiation and metastasis, proposing promising strategies to target the mechanisms, aiming to inhibit tumor growth and disease progression.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 174-190"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000164/pdfft?md5=d7bd869d5f29eb7c6e155b9974fa10d6&pid=1-s2.0-S2543106424000164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging lean 4.0 technologies in healthcare: An exploration of its applications","authors":"Mohd Javaid ,&nbsp;Abid Haleem ,&nbsp;Ravi Pratap Singh ,&nbsp;Sumit Gupta","doi":"10.1016/j.abst.2024.08.001","DOIUrl":"10.1016/j.abst.2024.08.001","url":null,"abstract":"<div><p>Lean 4.0, a fusion of lean manufacturing and digital technologies, is a powerful tool for implementing Industry 4.0. Its widespread use across sectors is driven by its ability to eliminate waste, reduce errors, boost revenue, and enhance customer care and efficiency. In the healthcare sector, this fourth lean revolution is particularly beneficial, as it helps to curb wastage and enhance efficiency, leading to more effective outcomes. Lean 4.0, a globally recognized best practice for industrial organisations, has proven its worth in enhancing performance and competitiveness. Its success has led to its adoption not only in manufacturing but also in non-manufacturing sectors such as Healthcare, finance, telecommunications, construction, and logistics. Its ease of use and effectiveness make it a superior alternative to traditional medical waste management techniques. Relevant papers on Lean 4.0 for Healthcare in the current literature are identified and studied to evaluate the impact of Lean 4.0 principles in Healthcare. This review-based research studies Lean 4.0 technologies and their needs in Healthcare. It discusses sustainable support for the healthcare sphere through Lean 4.0. Paper briefs several modalities of Lean 4.0 for the healthcare domain. Finally, the paper identifies and discusses the significant applications of Lean 4.0 in Healthcare. Lean 4.0 is essential to lowering errors that lead to medical mistakes since this business deals with life-or-death situations. Healthcare institutions need to reduce their overall waste reduction. With Lean 4.0, staff members working in quality management, clinical operations, consulting, and patient experience can progress into leadership roles in the healthcare sector. Lean 4.0 technologies can reduce waste production, including employing reusable medical equipment or cutting down on packaging waste. The possible difficulty of integrating digital technologies with healthcare systems and practices is Lean 4.0's limitations for the healthcare industry. Healthcare institutions can use refillable syringes and other disposable items to reduce waste rather than disposable plastic syringes. In future, healthcare institutions may save costs and lessen their environmental effect by minimising trash by using lean 4.0 technologies.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 138-151"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000127/pdfft?md5=cb3207d4120894b22c39ecd012cbb1b4&pid=1-s2.0-S2543106424000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomedicine in cancer therapy: Advancing precision treatments","authors":"Abdullahi Tunde Aborode ,&nbsp;Ayomide Samson Oluwajoba ,&nbsp;Aminat Modupe Ibrahim ,&nbsp;Shahzaib Ahmad ,&nbsp;Aashna Mehta ,&nbsp;Osasere Jude-Kelly Osayawe ,&nbsp;Damilola Oyebode ,&nbsp;Oluwaseun Akinsola ,&nbsp;Abraham Osinuga ,&nbsp;Isreal Ayobami Onifade ,&nbsp;Ibrahim O. Adelakun ,&nbsp;Ridwan Olamilekan Adesola ,&nbsp;Taiwo Bakare Abidola ,&nbsp;Adedeji Daniel Ogunyemi ,&nbsp;Oluwaseun Adeolu Ogundijo ,&nbsp;Olamilekan Gabriel Banwo ,&nbsp;Chibuzo H. Obiechefu","doi":"10.1016/j.abst.2024.06.003","DOIUrl":"https://doi.org/10.1016/j.abst.2024.06.003","url":null,"abstract":"<div><p>The progress made in the field of nanotechnology has resulted in the development of nanomedicine agents, which have demonstrated their efficacy as a promising clinical tool in the fight against different types of cancers. Furthermore, Nanomedicine products possess the potential to achieve intricate targeting strategies and multifunctionality. Currently, nanoparticles possess diverse applications across various scientific disciplines and serve as a crucial component in contemporary medical practices. The specimens have undergone analysis for diverse clinical purposes, including serving as drug carriers, delivering tumor genes, and functioning as contrast compounds in imaging. Diverse nanomaterials derived from organic, inorganic, lipid, or glycan compounds, in addition to synthetic polymers, have been employed to advance and enhance novel cancer therapeutics. The present review centers on the utilization of nanoparticles in clinical settings for the purposes of cancer diagnosis and treatment, with a particular emphasis on their function as drug carriers and targeted therapy agents.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 105-119"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000103/pdfft?md5=047f325cd4a8218462e22114585218a1&pid=1-s2.0-S2543106424000103-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141484836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of miR-361-3p in gastric cancer therapeutics and tumor progression","authors":"Kulsum Akhtar ,&nbsp;Gowhar Rashid ,&nbsp;Tahseen Bilal Rather ,&nbsp;Irfan Maqbool ,&nbsp;Ishrat Parveiz ,&nbsp;Gulzar Ahmad Bhat ,&nbsp;Fazl Q. Parray ,&nbsp;Syed Besina Yasin ,&nbsp;Syed Mudassar","doi":"10.1016/j.abst.2024.11.002","DOIUrl":"10.1016/j.abst.2024.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer (GC) remains a leading cause of cancer-related deaths globally. Even with advancements in treatment, it is not known precisely which molecular pathways cause GC to proceed. MicroRNAs, often referred to as small noncoding RNAs, have a crucial role in regulating gene expression, which impacts cancer growth, metastasis, and treatment resistance. Among these, miR-361–3p has drawn interest due to its possible role in the development of human cancer. While accumulating evidence highlights miR-361–3p involvement in various cancers, its precise biological function in gastric cancer remains largely unclear.</div></div><div><h3>Methodology</h3><div>The expression levels of miR-361–3p in gastric cancer tissues were compared with those of adjacent non-cancer tissues using real-time quantitative PCR (qRT-PCR). The investigation involved a thorough examination of the expression of miR-361–3p in GC samples in order to identify any possible correlations with clinicopathological characteristics.</div></div><div><h3>Results</h3><div>In 64.86 % of gastric cancer, expression levels of miR-361–3p mRNA were significantly reduced, which indicates that it may play a potential role in the pathophysiology of GC. However, no significant association has been found between miR-361–3p expression levels and clinical pathological features, such as tumor size, phase, or involvement of lymph nodes. This suggests that although miR-361–3p may contribute to GC progress, it is not related to traditional clinical markers.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 260-264"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of urinary proteome in the first two days after mating in male rats","authors":"Haitong Wang,&nbsp;Chenyang Zhao,&nbsp;Youhe Gao","doi":"10.1016/j.abst.2024.08.003","DOIUrl":"10.1016/j.abst.2024.08.003","url":null,"abstract":"<div><h3>Objective</h3><p>To explore whether differences between male rats on the next day of mating and on the day of mating can be reflected by the urine proteome.</p></div><div><h3>Methods</h3><p>Urine samples were collected from male Sprague-Dawley rats on the day of mating and the next day of mating. Urine samples were analysed by the label-free quantitative proteomics technique of high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Differential proteins of the urine proteome were analysed for protein function and biological pathways.</p></div><div><h3>Results</h3><p>54 differential proteins were identified by comparing the urine proteome of rats on the next day of mating with that on the day of mating, and nearly two-thirds of the differential proteins were related to spermatogenesis.</p></div><div><h3>Conclusions</h3><p>The urine proteome has the potential to reflect spermatogenesis without interfering with it.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 166-173"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000140/pdfft?md5=46d51b65f70f0cc0a9a8b2614e279c71&pid=1-s2.0-S2543106424000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of vitamin B12 and vitamin D in T2DM patients in north Indian population","authors":"Ishdeep Singh,&nbsp;Vivek Kumar Garg","doi":"10.1016/j.abst.2024.09.001","DOIUrl":"10.1016/j.abst.2024.09.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetes mellitus, highly prevalent endocrine disorder and metformin is the most frequently recommended oral hypoglycemic agent (OHA).</div></div><div><h3>Methods</h3><div>We recruited 100 individuals who were taking OHA including metformin more than one year as cases and 40 healthy individuals as control. The patients were divided into three groups. The first group, Group I (n = 58) patients taking metformin, group II (n = 42) patients taking OHA other than metformin and group III (n = 40), taken as control group.</div></div><div><h3>Results</h3><div>In groups I, II, and III, a considerable number of patients experienced low levels of vitamin B12 i.e. 42 (72.41 %), 8 (19.05 %), and 14 (35 %) respectively. When comparing all groups, p-value was highly significant (p = 0.000). 35 (60.36 %), 13(30.95 %), and 15(37.5 %) patients had insufficient levels of vitamin D in groups I, II, III respectively. On comparing, p-value was highly significant (p = 0.007).</div></div><div><h3>Conclusion</h3><div>The study concluded that long-term metformin treatment causes insufficiency and deficiency of vitamin D and vitamin B12, respectively.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 209-216"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-environment interactions and colorectal cancer risk: A case-control study on xenobiotic metabolizing enzyme polymorphisms in the Jammu& Kashmir, India population","authors":"Gowhar Rashid ,&nbsp;Gulzar A. Bhat ,&nbsp;Tahseen Bilal Rather ,&nbsp;Kulsum Akhter ,&nbsp;Ishrat Parveiz ,&nbsp;Irfan Maqbool ,&nbsp;Syed Nisar Ahmad ,&nbsp;Malik Tariq Rasool ,&nbsp;Farooq Ahmad Jan ,&nbsp;Syed Mudassar","doi":"10.1016/j.abst.2024.10.001","DOIUrl":"10.1016/j.abst.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Cancer remains a significant global health concern, with colorectal cancer (CRC) showing a rising incidence, particularly among younger populations. Most CRC cases are linked to a complex interplay of genetic and environmental factors. The cytochrome P450 (CYP) superfamily, including enzymes like CYP2A13 and CYP2A6, plays a vital role in metabolizing environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) and nitrosamines. Polymorphisms in these genes, alongside phase II glutathione-S-transferases (GSTs) involved in detoxification, can influence individual cancer risk. This study focuses on the association between these genetic polymorphisms and CRC risk in the Jammu &amp; Kashmir, population, a region with high exposure to dietary and lifestyle-related carcinogens.</div></div><div><h3>Methodology</h3><div>This hospital-based case-control study was conducted at the Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&amp;K, India between March 2019 and March 2022. The study included 246 histopathologically confirmed colorectal cancer (CRC) cases, and an equal number of matched controls based on age (±5 years), gender, and place of residence. Blood samples were collected for DNA extraction, followed by genotyping of xenobiotic-metabolizing enzyme (XME) genes, including CYP2A13, CYP2A6, and GSTs using standard PCR-RFLP and multiplex PCR methods. Statistical analyses were performed using STATA software to assess the association between gene polymorphisms and CRC risk.</div></div><div><h3>Results</h3><div>The study revealed key associations between genetic and environmental factors and CRC risk. The analysis demonstrated that cases had significantly lower education levels than controls. Family history of cancer, smoking, and dietary factors like red meat and salt tea consumption were more prevalent among cases. Genetic analysis identified significant interactions between various CYP and GST genotypes, and environmental factors such as smoking, pesticide exposure, and diet, with varying effects on CRC risk.</div></div><div><h3>Conclusion</h3><div>The research underscores the influence of genetic and environmental factors on colorectal cancer (CRC) risk. Lower educational was associated with a heightened risk of CRC. Certain genotype variants of xenobiotic metabolizing enzymes (XME) were found to increase CRC risk, particularly in conjunction with smoking, pesticide exposure, and sun-dried vegetable consumption. A family history of cancer, especially CRC, further amplified the risk. These findings emphasize the importance of developing personalized CRC prevention and screening strategies that account for gene-environment interactions.</div></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 227-241"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paper based molecularly imprinted SERS substrate for early detection of lysophosphatidic acid in ovarian cancer","authors":"Nazia Tarannum ,&nbsp;Deepak Kumar ,&nbsp;Akanksha Yadav ,&nbsp;Anil K. Yadav","doi":"10.1016/j.abst.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.abst.2024.03.001","url":null,"abstract":"<div><p>The current study is related to fabrication of point-of-care molecularly imprinted paper-based analytical devices, specifically related to ovarian cancer early stage detection. The task involves creating a paper coated with silver nanoparticles (AgNPs) that can be used as a transducer via surface enhanced Raman spectroscopy (SERS) to detect the threshold level of the biomarker lysophosphatidic acid (LPA) as a template molecule to diagnose ovarian cancer. MIPs are synthetic receptors designed for a targeted molecule which are prepared from polymers in the presence of target such as small molecules, proteins or cells etc. Removal of the template results in cavities which are structurally and electrostatically complementary to the template molecule. The molecularly imprinted polymer (MIP) layer was anchored on vinyl trimethoxy silane modified-paper, which served as a detector by hydrolytically modifying the paper surface with vinyl trimethoxy silane. To detect LPA in serum samples for ovarian cancer, MIP-paper based on SERS was developed. Patients with benign ovarian tumors had an LPA level of 7.73 μM whereas those with ovarian cancer have a level of 16.99 μM. A healthy person's LPA level is 2.92 μM. Consequently, the rise in LPA levels may aid in the early detection of ovarian cancer. The study refers to the use of a point of care device to diagnose ovarian cancer early, which should be simple, effective, and cost-effective. The analytical tool in the study is a sensor with high selectivity and sensitivity, quick assay times, and inexpensive costs. For LPA in serum, the binding constant of modified paper-based MIP ranges from 11.00 μM to 0.08 μM. The amalgamation of nanoparticles on 2D-paper with MIP have lead to develop sensor which can effectively select LPA in untreated real samples like serum.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":"6 ","pages":"Pages 46-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254310642400005X/pdfft?md5=7c83ba4ed035c0849ec0fbb408562405&pid=1-s2.0-S254310642400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140339801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}